Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis

Abstract : Abstract Background Humoral response against sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after two doses of BNT162b2 (Pfizer-BioNTech) has been proven to be less intense in maintenance dialysis patients as compared with healthy subjects, leading the French authorities to recommend a third injection in this population. Here we investigated the response to the third injection in two cohorts of haemodialysis (HD) patients. Methods Data from two prospective observational cohorts were collected. In the first (‘systematic’) cohort, patients from two HD centres (n = 66) received a third injection of BNT162b2, regardless of the response after two injections. In the second (‘conditional’) cohort, the injection was only prescribed to patients (n = 34) with no or low response to the previous two doses. In both cohorts, the third dose was injected 1–2 months after the second dose. Serology was performed after the second and third doses to assess anti-Spike immunoglobulin G (S IgG) antibody titre. Results In the systematic cohort, anti-S IgG was found in 83.3 and 92.4% of patients after the second and third doses of BNT162b2, respectively. In this cohort, 6/11 (54.5%) and 20/21 (95.2%) patients switched from non-responder to low responder and from low responder to high responder, respectively. In low and high responders to two doses, 50/55 (90.9%) at least doubled their anti-S IgG titre. Similar trends were observed in the conditional cohort. Conclusions In maintenance HD patients, humoral response against SARS-CoV-2 was boosted after a third dose of BNT162b2, allowing seroconversion in more than half of non-responders. These data may support an intensified vaccination protocol with a third dose of BNT162b2 in dialysis patients.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Véronique Bourgeais Connectez-vous pour contacter le contributeur
Soumis le : mardi 23 novembre 2021 - 14:13:24
Dernière modification le : vendredi 1 avril 2022 - 03:57:41

Lien texte intégral



Marine Dekervel, Nicolas Henry, Massimo Torreggiani, Lise-Marie Pouteau, Jean-Paul Imiela, et al.. Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis. Clinical Kidney Journal, Oxford University Press, 2021, 14 (11), pp.2349-2355. ⟨10.1093/ckj/sfab152⟩. ⟨hal-03443207⟩



Consultations de la notice